Q3 Net Loss Widens to $6.2M as HS Trial Accelerates to Q1 2027
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics posted a $6.2 million Q3 2026 net loss, or $(0.21) per share, versus $1.9 million a year earlier. Most of the gap is non-cash: a $3.3 million derivative remeasurement plus $0.6 million of deferred offering cost amortization, while operating expenses were roughly flat at $2.0 million. Cash stood at $10.4 million on September 30, which management says funds the Phase 2b atopic dermatitis trial and the planned Phase 2a HS trial into Q3 2027 — a going-concern overhang that has followed the stock since the Q2 10-Q. The operating news is the timing shift: the ~80-patient HS Phase 2a now starts in Q1 2027, ahead of the prior Q2 target, and Phase 2b atopic dermatitis topline is expected in Q1 2027 with no dropouts recorded to date. The release also recaps the full 50-patient Stage 1 data (59.3% clear or almost clear vs 30.4% vehicle at four weeks) already reported in October. Q1 2027 is the binary window — two trial readouts/launches land in the same quarter.
Updates
· SEC 8-K — Turn Therapeutics' Q3 2026 net loss of $6.2 million included a $3.3 million derivative remeasurement and $0.6 million of deferred offering cost amortization; cash was $10.4 million.
At the time of this announcement, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.